摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

苯甲酸 2-苯氧基乙基酯 | 4173-59-5

中文名称
苯甲酸 2-苯氧基乙基酯
中文别名
苯甲酸2-苯氧基乙基酯
英文名称
β-phenoxyethyl benzoate
英文别名
<2-Phenoxy-ethyl>benzoat;1-benzoyloxy-2-phenoxy-ethane;1-Benzoyloxy-2-phenoxy-aethan;2-Phenoxyethyl Benzoate
苯甲酸 2-苯氧基乙基酯化学式
CAS
4173-59-5
化学式
C15H14O3
mdl
——
分子量
242.274
InChiKey
WMAXFAQWCDUBLS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    18
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2916310090

SDS

SDS:bf2efc19b7ba9b1599939d94547fe1d9
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    苯甲酸 2-苯氧基乙基酯劳森试剂 作用下, 以 乙醚甲苯 为溶剂, 反应 0.03h, 生成 [(2-phenoxyethoxy)methyl]benzene
    参考文献:
    名称:
    Formation of ethers by the reductive desulfurization of thiono esters
    摘要:
    DOI:
    10.1021/jo00155a048
  • 作为产物:
    描述:
    己二酸,聚合2,2-二甲基-1,3-丙二醇和2,5-呋喃二酮,苯酸酯氢氧化钾苯甲酸 作用下, 以99.4%的产率得到苯甲酸 2-苯氧基乙基酯
    参考文献:
    名称:
    Solubilizing agents for active or functional organic compounds
    摘要:
    一种活性或功能性有机化合物被溶解在含有极性或极性化功能基团的二芳基有机化合物中,作为溶剂、共溶剂或添加剂,以形成其组合物。代表性的活性或功能性有机化合物包括个人护理产品中存在的那些,例如含有UVA/UVB吸收化合物的防晒霜,如二苯甲酮、苯甲酮-3和4-甲基苯基亚甲基樟脑。这些组合物还表现出增加的SPF、UVA/UVB吸收比例和临界波长性能特性。
    公开号:
    US20050152858A1
点击查看最新优质反应信息

文献信息

  • New Ring Opening Reactions of Oxiranes with Aryl Carboxylates
    作者:Kazutoshi Funahashi
    DOI:10.1246/bcsj.52.1488
    日期:1979.5
    Oxiranes reacted with aryl esters in the presence of base. The reactions of aryl carboxylates with alkyloxiranes afforded almost exclusively 1-alkyl-2-(aryloxy) ethyl carboxylates, whereas the reactions with aryloxiranes gave a mixture of 1-aryl-2-(aryloxy) ethyl carboxylates and 2-aryl-2-(aryloxy) ethyl carboxylates. Similar results were also obtained in the reaction with S-aryl thiocarboxylates and diaryl carbonates. The rate of reaction between phenyl acetate and phenoxymethyloxirane (PMO) in the presence of tributylamine (n-Bu3N) as a catalyst has been determined in the temperature range 110 to 130 °C and may be expressed by –d[PMO]⁄dt=k2[n-Bu3N]·[PMO]. The apparent activation energy calculated from the Arrhenius plots is 85.8 kj/mol. The reaction catalyzed by tributylamine is assumed to proceed through zwitter ions, n-Bu3\overset+NCH2CH(R)O− and n-Bu3\overset+NCH(R)CH2O−, which attack aryl carboxylate.
    在碱存在下,环氧乙烷与芳基酯反应。烷基环氧乙烷与芳基羧酸酯的反应主要生成1-烷基-2-芳氧基乙基羧酸酯,而芳基环氧乙烷的反应则生成1-芳基-2-芳氧基乙基羧酸酯和2-芳基-2-芳氧基乙基羧酸酯的混合物。在硫代芳基羧酸酯和二芳基碳酸酯与环氧乙烷的反应中也得到了类似的结果。在110至130°C的温度范围内,测定了苯甲酸乙酯与苯氧甲基环氧乙烷(PMO)在三丁胺(n-Bu3N)催化下的反应速率,可以用-d[PMO]/dt=k2[n-Bu3N]·[PMO]表示。从阿伦尼乌斯图计算出的表观活化能为85.8 kJ/mol。三丁胺催化的反应被认为是通过两性离子进行的,n-Bu3\overset+NCH2CH(R)O−和n-Bu3\overset+NCH(R)CH2O−,它们攻击芳基羧酸酯。
  • Response to Inhaled Nitric Oxide in Premature and Term Neonates
    作者:Thomas Hoehn、Martin F. Krause
    DOI:10.2165/00003495-200161010-00004
    日期:——
    Inhaled nitric oxide (iNO) has emerged as a promising therapeutic agent in the treatment of persistent pulmonary hypertension of the newborn. Several theories exist regarding causes of both response and nonresponse to iNO. Clinical trials differentiate disease entities (primary vs secondary persistent pulmonary hypertension associated with meconium aspiration syndrome, pneumonia or congenital diaphragmatic hernia) and their specific response rates. iNO combined with high-frequency ventilation appears to be superior to inhalation of nitric oxide (NO) during conventional ventilation. Little is known regarding the role of the degree of lung expansion and its modification — no matter what mode of ventilation is applied. Gestational age plays an important role in relation to the potential adverse effects of NO. Of particular concern in the premature neonate is the effect of NO on bleeding time and the inhibition of platelet aggregation. Those potentially hazardous effects need to be carefully weighed against early intervention with iNO at a comparably low oxygenation index in order to prevent the vicious cycle of hypoxaemia and subsequent increased right-to-left shunting. Further studies are required to determine the optimal timing, mode of delivery and mode of ventilation used with iNO therapy in order to optimise the response of premature and term neonates.
    吸入一氧化氮(iNO)已成为治疗新生儿持续性肺动脉高压的一种很有前景的治疗药物。关于对 iNO 有反应和无反应的原因存在多种理论。临床试验对疾病实体(与胎粪吸入综合征、肺炎或先天性膈疝相关的原发性和继发性持续性肺动脉高压)及其具体反应率进行了区分。 iNO 与高频通气相结合似乎优于在常规通气过程中吸入一氧化氮(NO)。无论采用哪种通气模式,人们对肺扩张程度的作用及其改变知之甚少。妊娠年龄对一氧化氮的潜在不良影响起着重要作用。早产新生儿尤其需要关注 NO 对出血时间和血小板聚集抑制的影响。为了防止低氧血症的恶性循环以及随之而来的右向左分流的增加,需要仔细权衡这些潜在的有害影响与在氧合指数相当低的情况下尽早使用 iNO 进行干预的利弊。需要进一步研究确定 iNO 治疗的最佳时机、分娩方式和通气模式,以优化早产儿和足月新生儿的反应。
  • Process for preparing alkoxy or arylmethoxy aroxyethanes
    申请人:Appleton Papers Inc.
    公开号:US20020002311A1
    公开(公告)日:2002-01-03
    The present invention is a novel process, with or without solvent, for manufacture of compounds of the formula 1 wherein P is selected from phenyl and naphthyl; wherein R 1 and R 2 and R 3 are each independently selected from hydrogen, alkyl, alkoxy, aryl, aralkyl, aralkoxy, halogen, alkoxyalkoxy, and aralkoxyalkoxy; wherein R 5 is selected from substituted or unsubstituted phenyl, and substituted or unsubstituted naphthyl, the substituents being each independently selected from alkyl (C 1 -C 8 ), alkoxy (C 1 -C 8 ), aroxy, aralkoxy (C 1 -C 8 ) and halogen. The process comprises reacting substituted phenols or naphthols of the formula 2 with ethylene carbonate in the presence of a first catalyst selected from metal halide, quarternary ammonium halide and quarternary phosphonium halide thereby forming an intermediate of the formula 3 then reacting the intermediate with a first compound selected from alkyl or aralkylhalide, alkyl or aralkyl sulfate, and alkyl or aralkyl sulfonate together with a metal hydroxide in the presence of a second catalyst, the second catalyst selected from quarternary ammonium salt or quarternary phosphonium salt.
    本发明是一种新型工艺,可有溶剂或无溶剂,用于制造式1的化合物,其中P选择自苯基和萘基;其中R1、R2和R3各自独立地选择自氢、烷基、烷氧基、芳基、芳基烷基、芳基烷氧基、卤素、烷氧基烷氧基和芳基烷氧基烷氧基;其中R5选择自取代或未取代的苯基和取代或未取代的萘基,取代基各自独立地选择自烷基(C1-C8)、烷氧基(C1-C8)、芳氧基、芳基烷氧基(C1-C8)和卤素。该工艺包括在第一催化剂的存在下,将式2的取代苯酚或萘酚与碳酸乙烯酯反应,从而形成式3的中间体,然后在第二催化剂的存在下,将中间体与选择自烷基或芳基烷基卤化物、烷基或芳基烷基硫酸盐和烷基或芳基烷基磺酸盐的第一化合物以及金属羟化物反应。第二催化剂选择自季铵盐或季磷盐。
  • LOW/ZERO VOC GLYCOL ETHER-ESTERS AND USE AS CLEAN-UP SOLVENTS AND PAINT THINNERS
    申请人:DONATE Felipe A.
    公开号:US20120259049A1
    公开(公告)日:2012-10-11
    This invention relates to a clean-up solvent and paint thinner for solvent-borne resins and coatings selected from compositions of Formula (I) wherein R 1 is a C 1 -C 10 alkyl group, phenyl or benzyl, R 2 is either hydrogen or methyl, R 3 is a carbon chain including 4-6 carbon atoms, and n=2-4; of Formula (II) wherein R 1 and R 4 are, independently, C 1 -C 10 alkyl groups, phenyl or benzyl, R 2 is either hydrogen or methyl, R 3 is a carbon chain including 0-4 carbon atoms, and n=1-4; and mixtures thereof. The invention also relates to a solvent-borne composition including a solvent-borne polymer and the low and zero VOC composition of the invention; and a method for cleaning or thinning a solvent-borne composition.
    本发明涉及一种用于溶剂型树脂和涂料的清洗溶剂和稀释剂,所选的组成物来自以下化学式(I)或(II)的组合:其中R1是C1-C10烷基,苯基或苄基,R2是氢或甲基,R3是包括4-6个碳原子的碳链,n=2-4;或者其中R1和R4是独立的C1-C10烷基,苯基或苄基,R2是氢或甲基,R3是包括0-4个碳原子的碳链,n=1-4;以及它们的混合物。本发明还涉及一种包括溶剂型聚合物和本发明的低和零VOC组成物的溶剂型组合物;以及一种清洗或稀释溶剂型组合物的方法。
  • GLYCOL ETHER ARYL ESTER PLASTICIZER
    申请人:Eastman Chemical Company
    公开号:US20220227962A1
    公开(公告)日:2022-07-21
    Disclosed is the use of glycol ether aryl ester plasticizers as viscosity reducing agents in plastisols comprising di(2-ethylhexyl) terephthalate, 1,2-cyclohexane dicarboxylic acid diisononyl ester, or diisononyl phthalate as the primary plasticizer. The glycol ether aryl ester plasticizers improve viscosity and viscosity stability while maintaining or improving plastisol properties such as Shore A Hardness and fusion time.
    本发明揭示了在含有二(2-乙基己基)对苯二甲酸酯、1,2-环己烷二羧酸二异壬酯或异壬酸酯类主要增塑剂的浆料中,使用乙二醇醚芳基酯增塑剂作为粘度降低剂。乙二醇醚芳基酯增塑剂提高了粘度和粘度稳定性,同时保持或提高了浆料的性能,例如Shore A硬度和熔合时间。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐